nuvolanevicata / Shutterstock.com
20 March 2015Big PharmaTrevor Cook
Market exclusivity: Lucky orphans
Since 2001, the EU has had under Regulation No. 141/2000 a modified regulatory regime that provides incentives to develop orphan medicinal products—those that treat rare diseases with patient populations of generally less than 250,000—within the EU.
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/7eba27a0-50e4-11f0-9c85-f9a65cb3cc5f-Coke%20Morgan%20Stewart(1).webp)